Should I buy or sell MeiraGTx stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MGTX shares. View MGTX analyst ratings or view top-rated stocks .

What is MeiraGTx's stock price target for 2024?

2 Wall Street analysts have issued 1 year price objectives for MeiraGTx's shares. Their MGTX share price targets range from $11.00 to $41.00. On average, they anticipate the company's share price to reach $25.67 in the next twelve months. This suggests a possible upside of 410.3% from the stock's current price. View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts .

How have MGTX shares performed in 2024?

MeiraGTx's stock was trading at $7.02 on January 1st, 2024. Since then, MGTX shares have decreased by 28.3% and is now trading at $5.03. View the best growth stocks for 2024 here .

When is MeiraGTx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our MGTX earnings forecast .

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.01. The business earned $2.04 million during the quarter, compared to the consensus estimate of $10.13 million. MeiraGTx had a negative net margin of 599.47% and a negative trailing twelve-month return on equity of 114.33%.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV) , Sorrento Therapeutics (SRNE) , Aldeyra Therapeutics (ALDX) , Inovio Pharmaceuticals (INO) , Kadmon (KDMN) , Pfizer (PFE) , VBI Vaccines (VBIV) , Novavax (NVAX) , Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD) .

When did MeiraGTx IPO?

MeiraGTx (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Alexandria Forbes , Elizabeth A Cook, Perceptive Advisors Llc, Richard Giroux , Robert J Wollin, Robert K Zeldin and Stuart Naylor . View institutional ownership trends .

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MGTX

MeiraGTx (MGTX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free MGTX Stock Alerts

$5.05

+0.04 (+0.80%)

(As of 03:39 PM ET)

Compare

Today's Range: $4.89
▼
$5.12
50-Day Range: $5.01
▼
$6.70
52-Week Range: $3.49
▼
$8.35

Volume: 145,129 shs
Average Volume: 154,534 shs
Market Capitalization: $324.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.67

Get MeiraGTx alerts:

MeiraGTx MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 410.3% Upside
$25.67 Price Target
Short Interest: Healthy
1.79% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.54
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.40) to $0.90 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

192nd out of 918 stocks

Biological Products, Except Diagnostic Industry

19th out of 151 stocks

3.5

Analyst's Opinion

Consensus Rating
MeiraGTx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
MeiraGTx has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.79% of the outstanding shares of MeiraGTx have been sold short.
Short Interest Ratio / Days to Cover
MeiraGTx has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in MeiraGTx has recently decreased by 8.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MeiraGTx does not currently pay a dividend.
Dividend Growth
MeiraGTx does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MeiraGTx has received a 78.28% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for MeiraGTx is -0.54.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for MeiraGTx this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MeiraGTx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.70% of the stock of MeiraGTx is held by insiders.
Percentage Held by Institutions
67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MeiraGTx are expected to grow in the coming year, from ($1.40) to $0.90 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MeiraGTx is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MeiraGTx is -3.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MeiraGTx has a P/B Ratio of 2.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About MeiraGTx Stock (NASDAQ:MGTX)

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

MGTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MGTX Stock News Headlines

April 18, 2024 | globenewswire.com

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

March 17, 2024 | finance.yahoo.com

MGTX Apr 2024 12.500 call

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Meiragtx Holdings’ Promising Pipeline and Strategic Partnerships Set Stage for Growth

March 14, 2024 | investorplace.com

MGTX Stock Earnings: MeiraGTx Hldgs Beats EPS, Misses Revenue for Q4 2023

March 14, 2024 | benzinga.com

Recap: MeiraGTx Hldgs Q4 Earnings

March 14, 2024 | hk.finance.yahoo.com

MeiraGTx Holdings PLC Reports Notable Clinical Progress Amidst Financial Challenges in 2023

March 14, 2024 | baystreet.ca

Meira Retreats on Financial Figures

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 14, 2024 | globenewswire.com

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

February 26, 2024 | finance.yahoo.com

MeiraGTx Holdings plc (NASDAQ:MGTX) stock most popular amongst private equity firms who own 28%, while individual investors hold 26%

February 17, 2024 | finance.yahoo.com

MGTX Mar 2024 12.500 call

February 16, 2024 | seekingalpha.com

MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met

February 15, 2024 | morningstar.com

MeiraGTx Holdings PLC MGTX

February 13, 2024 | finance.yahoo.com

MeiraGTx Announces $50 Million Milestone from Janssen Pharmaceuticals

January 10, 2024 | finance.yahoo.com

Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet

January 10, 2024 | finance.yahoo.com

MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions

December 25, 2023 | finance.yahoo.com

Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade

December 24, 2023 | benzinga.com

MeiraGTx Hldgs Stock (NASDAQ:MGTX), Short Interest Report

December 23, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: NeuroPace (NPCE), Meiragtx Holdings (MGTX) and Jazz Pharmaceuticals (JAZZ)

December 22, 2023 | benzinga.com

MeiraGTx Hldgs Stock (NASDAQ:MGTX) Dividends: History, Yield and Dates

December 21, 2023 | marketwatch.com

MeiraGTx Shares Rise 20% After Asset Purchase Deal With Janssen Pharma

December 21, 2023 | msn.com

MeiraGTx signs asset purchase agreement for bota-vec collaboration with Janssen

December 21, 2023 | msn.com

Why Is Eye Disease Related Gene Therapy Focused MeiraGTx Stock Soaring Today?

December 21, 2023 | finance.yahoo.com

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

December 14, 2023 | finance.yahoo.com

The past three years for MeiraGTx Holdings (NASDAQ:MGTX) investors has not been profitable

November 15, 2023 | finance.yahoo.com

MeiraGTx Holdings PLC Reports Q3 2023 Financial Results and Operational Progress

See More Headlines

Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:MGTX
CUSIP: N/A
CIK: 1735438
Web: www.meiragtx.com
Phone: (646) 860-7985
Fax: N/A
Employees: 419
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $25.67
High Stock Price Target: $41.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +412.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-84,030,000.00
Net Margins: -599.47%
Pretax Margin: -599.47%
Return on Equity: -114.33%
Return on Assets: -42.56%

Debt

Debt-to-Equity Ratio: 0.62
Current Ratio: 2.38
Quick Ratio: 2.38

Sales & Book Value

Annual Sales: $14.02 million
Price / Sales: 22.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.17 per share
Price / Book: 2.31

Miscellaneous

Outstanding Shares: 64,220,000
Free Float: 57,988,000
Market Cap: $321.74 million
Optionable: Optionable
Beta: 1.29

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Alexandria Forbes Ph.D. (Age 59)
CEO, President & Director
Comp: $2.33M
Mr. Richard Brian Giroux B.A. (Age 51)
COO & CFO
Comp: $1.83M
Dr. Stuart Naylor Ph.D. (Age 61)
Chief Development Officer
Comp: $1M
Mr. Robert J. Wollin J.D. (Age 48)
General Counsel & Secretary
Dr. Michel Michaelides M.D.
Head of Clinical Ophthalmology
Ms. Christine Elise Sheehy (Age 56)
Senior Vice President of Global Integration
Mr. Tim Randall
Senior Vice President of Risk & Internal Controls
Dr. Alastair Leighton Ph.D.
Senior Vice President of Manufacturing & Supply Chain
Dr. Robert K. Zeldin M.D. (Age 61)
Chief Medical Officer
Comp: $1.1M

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MGTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MeiraGTx stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MGTX shares.
View MGTX analyst ratings or view top-rated stocks.
What is MeiraGTx's stock price target for 2024?: 2 Wall Street analysts have issued 1 year price objectives for MeiraGTx's shares. Their MGTX share price targets range from $11.00 to $41.00. On average, they anticipate the company's share price to reach $25.67 in the next twelve months. This suggests a possible upside of 410.3% from the stock's current price.
View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts.
How have MGTX shares performed in 2024?: MeiraGTx's stock was trading at $7.02 on January 1st, 2024. Since then, MGTX shares have decreased by 28.3% and is now trading at $5.03.
View the best growth stocks for 2024 here.
When is MeiraGTx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our MGTX earnings forecast.
How were MeiraGTx's earnings last quarter?: MeiraGTx Holdings plc (NASDAQ:MGTX) posted its quarterly earnings data on Thursday, March, 14th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by $0.01. The business earned $2.04 million during the quarter, compared to the consensus estimate of $10.13 million. MeiraGTx had a negative net margin of 599.47% and a negative trailing twelve-month return on equity of 114.33%.

What other stocks do shareholders of MeiraGTx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).
When did MeiraGTx IPO?: MeiraGTx (MGTX) raised $75 million in an initial public offering (IPO) on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.
Who are MeiraGTx's major shareholders?: MeiraGTx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.18%). Insiders that own company stock include Alexandria Forbes, Elizabeth A Cook, Perceptive Advisors Llc, Richard Giroux, Robert J Wollin, Robert K Zeldin and Stuart Naylor.
View institutional ownership trends.
How do I buy shares of MeiraGTx?: Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial